Payment overview · 2025
General Payments
$683.30
30 reported records · 15 companies
Healthcare provider profile · identity verified
Danna S Barkley
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BROOKLAND, AR · NPI 1740844927
Verified facts
What the public records show
CMS Open Payments records show Danna S Barkley received $683.30 in general payments during 2025 across 30 reported records.
UCB, Inc. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 333 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $143.97 | 21.1% | 5 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$93.99 | 13.8% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $69.37 | 10.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.12 | 9.5% | 3 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $48.12 | 7.0% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $40.61 | 5.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $38.28 | 5.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.11 | 4.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $27.53 | 4.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $25.92 | 3.8% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $22.33 | 3.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.13 | 3.2% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.42 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.36 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.04 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $683.30 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $114.18 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $96.23 | 4 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $93.99 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $69.37 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $48.12 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $40.61 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $38.28 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $29.79 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
333 | 60 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 343 | 107 |
| Eliquis | Apixaban | 333 | 60 |
| Potassium Chloride | Potassium Chloride | 323 | 87 |
| Furosemide | Furosemide | 283 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 270 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 243 | 61 |
| Gabapentin | Gabapentin | 235 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 40 |
| Lisinopril | Lisinopril | 141 | 38 |
| Myrbetriq | Mirabegron | 137 | suppressed |
| Mirtazapine | Mirtazapine | 135 | 38 |
| Carvedilol | Carvedilol | 115 | 21 |
| Trazodone Hcl | Trazodone Hcl | 113 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 35 |
| Sertraline Hcl | Sertraline Hcl | 103 | 22 |
| Losartan Potassium | Losartan Potassium | 98 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 30 |
| Tramadol Hcl | Tramadol Hcl | 80 | 37 |
| Jardiance | Empagliflozin | 79 | 16 |
| Donepezil Hcl | Donepezil Hcl | 77 | 20 |
| Buspirone Hcl | Buspirone Hcl | 76 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 70 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 12 |
| Simvastatin | Simvastatin | 64 | 15 |
| Levetiracetam | Levetiracetam | 60 | 15 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 58 | suppressed |
| Lorazepam | Lorazepam | 53 | 16 |
| Metformin Hcl | Metformin Hcl | 51 | 12 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 45 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 34 |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | 16 |
| Spironolactone | Spironolactone | 41 | 13 |
| Calcium Acetate | Calcium Acetate | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | 17 |
| Memantine Hcl | Memantine Hcl | 38 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Alprazolam | Alprazolam | 36 | suppressed |
| Cephalexin | Cephalexin | 36 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Prednisone | Prednisone | 36 | 17 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 14 |
| Nystatin | Nystatin | 34 | 15 |
| Lithium Carbonate | Lithium Carbonate | 33 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 33 | 17 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Nyamyc | Nystatin | 32 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Insulin Lispro | Insulin Lispro | 30 | 14 |
| Lacosamide | Lacosamide | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 29 | 18 |
| Baclofen | Baclofen | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 22 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | 11 |
| Cefdinir | Cefdinir | 23 | 19 |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 15 |
| Topiramate | Topiramate | 21 | suppressed |
| Sucralfate | Sucralfate | 20 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 14 |
| Clonidine Hcl | Clonidine Hcl | 19 | 11 |
| Latanoprost | Latanoprost | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 18 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 11 |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 15 | 13 |
| Vimpat | Lacosamide | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Tresiba | Insulin Degludec | 14 | suppressed |
| Admelog | Insulin Lispro | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Keppra | Levetiracetam | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $683.30 · 30 records | UCB, Inc. | AMYVID, CREXONT, Hizentra, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PRECIVITYAD2, REXULTI, Rystiggo, VALTOCO, VUMERITY, WAINUA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error